2011年第四季度进入Ⅲ期临床的最具潜力品种的跟踪报道
The Report of the Most Promising New Drugs that Entered Phase Ⅲ Clinical Study in the Fourth Quarter of 2011
摘要
本文主要介绍了2011年第四季度进入Ⅲ期临床研究的5个极具市场潜力的新药的市场前景和研发状况。
This paper reported the market prospects and recent clinical researches of the 5 most market promising new drugs which have entered Phase III clinical study.
出处
《国外医药（抗生素分册）》
CAS
2012年第6期249-252,267,共5页
World Notes on Antibiotics
关键词
新药
市场
临床实验
new drugs
market
clinical study
参考文献12
-
1Wyrwich KW, Spratt DI, Gass M, et al. Identifying meaningful differences in vasomotor symptoms among menopausal women[J]. Menopause, 2008,15(4Pt 1):698.
-
2Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial[J]. Jama, 172002, 288(3):321.
-
3Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial[J]. JAMA, 2003, 289(20):2651.
-
4Committee WsHIS. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative Randomized Controlled Trial[J]. 2004, 291:1701.
-
5Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial [J].Ann Intern Med, 2006, 145 (12):869.
-
6Cvoro A, Paruthiyil S, Jones JO, et al. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract[J]. Endocrinology, 2007, 148(2):538.
-
7http://bionovo.com/pipeline/menerba.
-
8Fleischmann R, Shen Z, Yeh LT, et al. a novel oral uricosuric agent,in combination with febuxostat shows significant additive urate lowering effects in gout patients with 100% response achieved for all combination dose regimens[J]. Ann Rheum Dis, 2011, 70(Suppl3): 188.
-
9http://www.currentpartnering.com/2012/04/25/astrazeneca- acquires-ardea-for- 1-26-billion-gains-Lesinurad.
-
10http://clinicaltrials.gov/ct2/show/NCT00633191.
-
1吴美强.丹皮酚测定方法研究概述[J].海峡药学,2010,22(2):59-60. 被引量：1
-
2开开.《药品说明书 怎么说明白》跟踪报道—药品未标有效期 购买服用须谨慎[J].质量跟踪,2001(11):7-7.
-
3刘毅,吴建敏,严菁,吴渭滨,林兰.熔点对照品标化研究[J].中国新药杂志,2015,24(3):264-265. 被引量：2
-
4张宇（摘）.04119 世界药物研发状况似有好转[J].国外药讯,2006(4):46-46.
-
5世界药物研发状况似有好转[J].中国医药技术与市场,2007,7(3):66-66.
-
6侯建鹏.2004中国医药大盘点[J].医药世界,2004(12):16-20.
-
7宋东伟,徐斌,王玉姝,兰华英.选择性雌激素受体调节剂组织选择性作用研究进展[J].现代药物与临床,2014,29(2):206-210. 被引量：7
-
8萧逸.新华鲁抗南京“救火”[J].中国药店,2004(12):16-16.
-
9朱精兵,洪东河.浅谈建立药学研究质量管理规范的必要性与可行性[J].中南药学,2016,14(2):217-220. 被引量：8
-
10姚磊,宁澄清,余聂芳.FLT3抑制剂的抗肿瘤研发现状[J].肿瘤药学,2015,5(1):1-13. 被引量：1
